| Heart disease and stroke statistics—2014 update: a report from the American Heart Association AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ... circulation 129 (3), e28-e292, 2014 | 56846* | 2014 |
| Angiotensin–neprilysin inhibition versus enalapril in heart failure JJV McMurray, M Packer, AS Desai, J Gong, MP Lefkowitz, AR Rizkala, ... New England Journal of Medicine 371 (11), 993-1004, 2014 | 7341 | 2014 |
| Dapagliflozin in patients with heart failure and reduced ejection fraction JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ... New England Journal of Medicine 381 (21), 1995-2008, 2019 | 6235 | 2019 |
| Spironolactone for heart failure with preserved ejection fraction B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ... New England Journal of Medicine 370 (15), 1383-1392, 2014 | 2732 | 2014 |
| Strategies for multivessel revascularization in patients with diabetes ME Farkouh, M Domanski, LA Sleeper, FS Siami, G Dangas, M Mack, ... New England journal of medicine 367 (25), 2375-2384, 2012 | 2202 | 2012 |
| Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ... New England Journal of Medicine 381 (17), 1609-1620, 2019 | 1966 | 2019 |
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ... New England Journal of Medicine 367 (23), 2204-2213, 2012 | 1661 | 2012 |
| Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ... New England Journal of Medicine 387 (12), 1089-1098, 2022 | 1577 | 2022 |
| Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial MA Pfeffer, B Claggett, SF Assmann, R Boineau, IS Anand, N Clausell, ... Circulation 131 (1), 34-42, 2015 | 988 | 2015 |
| Rehospitalization for heart failure: predict or prevent? AS Desai, LW Stevenson Circulation 126 (4), 501-506, 2012 | 814 | 2012 |
| Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure M Packer, JJV McMurray, AS Desai, J Gong, MP Lefkowitz, AR Rizkala, ... Circulation 131 (1), 54-61, 2015 | 803 | 2015 |
| 2017 cardiovascular and stroke endpoint definitions for clinical trials KA Hicks, KW Mahaffey, R Mehran, SE Nissen, SD Wiviott, B Dunn, ... Circulation 137 (9), 961-972, 2018 | 672 | 2018 |
| Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ... Circulation 139 (22), 2528-2536, 2019 | 638 | 2019 |
| Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not … SM Dunlay, MM Givertz, D Aguilar, LA Allen, M Chan, AS Desai, A Deswal, ... Circulation 140 (7), e294-e324, 2019 | 611 | 2019 |
| Treatment of anemia with darbepoetin alfa in systolic heart failure K Swedberg, JB Young, IS Anand, S Cheng, AS Desai, R Diaz, ... New England Journal of Medicine 368 (13), 1210-1219, 2013 | 597 | 2013 |
| SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials M Vaduganathan, KF Docherty, BL Claggett, PS Jhund, RA de Boer, ... The Lancet 400 (10354), 757-767, 2022 | 574 | 2022 |
| Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction SD Solomon, B Claggett, EF Lewis, A Desai, I Anand, NK Sweitzer, ... European heart journal 37 (5), 455-462, 2016 | 569 | 2016 |
| Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials AS Desai, JC Fang, WH Maisel, KL Baughman Jama 292 (23), 2874-2879, 2004 | 549 | 2004 |
| Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for … JJV McMurray, M Packer, AS Desai, J Gong, MP Lefkowitz, AR Rizkala, ... European journal of heart failure 15 (9), 1062-1073, 2013 | 533 | 2013 |
| PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ... N Engl J Med 381 (17), 1609-1620, 2019 | 515 | 2019 |
